NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB — from the NYSE American. The staff suspended trading in the Company’s common stock because the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of Directors of the Exchange (the “Committee”) had issued a decision in which it upheld the Exchange’s previously announced determination to delist the Company’s common stock.

The Exchange previously announced on July 28, 2023 that it had commenced delisting proceedings with respect to the Company’s common stock that same day pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period. The Company had the right to request a review of this delisting determination by the Panel.

The Company has a right to a review of the Panel’s decision to delist the common stock by the Committee by making a written request within 15 calendar days of the date of the Panel’s decision. The filing of an application with the Securities and Exchange Commission to delist the common stock is pending completion of all applicable procedures, including any appeal by the Company of the Panel’s decision.